FRM
MACK

Fox Run Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Fox Run Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,707
Closed -$87K – 847
2016
Q4 		$87K Buy
+2,707
New +$115K 0.05% 472

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fox Run Management's MACK Position: Q1 2017 in Review

Fox Run Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 2,707 shares — an estimated $87K sold.

Fox Run Management first reported a position in MACK in Q4 2016 and held it in 1 quarter. The position peaked at $87K in Q4 2016. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

  • Fox Run Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Fox Run Management sold 2,707 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $87K.
  • Fox Run Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Fox Run Management's Merrimack Pharmaceuticals, Inc. position peaked at $87K in Q4 2016.
  • 116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on Fox Run Management's 13F filing for Q1 2017, filed 17 Apr 2017.